About: Development and Evaluation of a Duo SARS-CoV-2 RT-qPCR Assay Combining Two Assays Approved by the World Health Organization Targeting the Envelope and the RNA-Dependant RNA Polymerase (RdRp) Coding Regions

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Development and Evaluation of a Duo SARS-CoV-2 RT-qPCR Assay Combining Two Assays Approved by the World Health Organization Targeting the Envelope and the RNA-Dependant RNA Polymerase (RdRp) Coding Regions Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
title	Development and Evaluation of a Duo SARS-CoV-2 RT-qPCR Assay Combining Two Assays Approved by the World Health Organization Targeting the Envelope and the RNA-Dependant RNA Polymerase (RdRp) Coding Regions
Creator	Charrel, Remi Nougairede, Antoine Coutard, Bruno Ninove, Laetitia Pezzi, Laura Durand, Guillaume De Lamballerie, Xavier Thirion, Laurence Leparc-Goffart, Isabelle Molle, Gregory
source	Medline; PMC
abstract	The recent emergence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) worldwide has highlighted the importance of reliable and rapid diagnostic testing to prevent and control virus circulation. Dozens of monoplex in-house RT-qPCR assays are already available; however, the development of dual-target assays is suited to avoid false-negative results caused by polymorphisms or point mutations, that can compromise the accuracy of diagnostic and screening tests. In this study, two mono-target assays recommended by WHO (E-Sarbeco (enveloppe gene, Charite University, Berlin, Germany) and RdRp-IP4 (RdRp, Institut Pasteur, Paris, France)) were selected and combined in a unique robust test; the resulting duo SARS-CoV-2 RT-qPCR assay was compared to the two parental monoplex tests. The duo SARS-CoV-2 assay performed equally, or better, in terms of sensitivity, specificity, linearity and signal intensity. We demonstrated that combining two single systems into a dual-target assay (with or without an MS2-based internal control) did not impair performances, providing a potent tool adapted for routine molecular diagnosis in clinical microbiology laboratories.
has issue date	2020-06-25(xsd:dateTime)
bibo:doi	10.3390/v12060686
bibo:pmid	32630601
has license	cc-by
sha1sum (hex)	4321dbbb6f4fe734b5f0d23051884e9dba5c268c
schema:url	https://doi.org/10.3390/v12060686
resource representing a document's title	Development and Evaluation of a Duo SARS-CoV-2 RT-qPCR Assay Combining Two Assays Approved by the World Health Organization Targeting the Envelope and the RNA-Dependant RNA Polymerase (RdRp) Coding Regions
has PubMed Central identifier	PMC7354606
has PubMed identifier	32630601
schema:publication	Viruses
resource representing a document's body	covid:4321dbbb6f4fe734b5f0d23051884e9dba5c268c#body_text
is schema:about of	named entity 'robust' named entity 'circulation' named entity 'equally' named entity 'Paris' named entity 'screening tests' named entity 'Polymerase' named entity 'Targeting' named entity 'MONOPLEX' named entity 'ROBUST' named entity 'PERFORMED' named entity 'DEVELOPMENT' named entity 'ADAPTED' named entity 'SIGNAL INTENSITY' named entity 'GENE' named entity 'IN-HOUSE' named entity 'VIRUS' named entity 'BETTER' named entity 'France' named entity 'based' named entity 'SARS-CoV-2' named entity 'Institut Pasteur' named entity 'molecular diagnosis' named entity 'potent' named entity 'tests' named entity 'study' named entity 'screening tests' named entity 'RdRp' named entity 'clinical microbiology' named entity 'RNA' named entity 'Dependant' named entity 'selected' named entity 'diagnostic testing' named entity 'performances' named entity 'Pathogens' named entity 'Thermo Fisher Scientific' named entity 'Charité' named entity 'Institut Pasteur' named entity 'viral genome' named entity 'RdRp' named entity 'RNA' named entity 'QSY' named entity 'RdRp' named entity 'WHO' named entity 'turnaround time' named entity 'IVT' named entity 'RNA' named entity 'serially diluted' named entity 'clinical samples' named entity 'BSL3' named entity 'correlation' named entity 'HRV' named entity 'deletions' named entity 'molecular biology' named entity 'RdRp' named entity 'asymptomatic' named entity 'ORF1' named entity 'LOD' named entity 'Thermo Fisher Scientific' named entity 'cytopathic effect' named entity 'IVT' named entity 'RT-qPCR' named entity 'false negative results' named entity '1.2' named entity 'RT-qPCR' named entity 'clinical samples' named entity 'SARS-CoV-2' named entity 'RNA viruses' named entity 'correlation coefficient' named entity 'France' named entity 'RNA transcript' named entity 'Cepheid' named entity 'clinical samples'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software